Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike

Executive Summary

A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.

You may also be interested in...



Antibiotic Limited Use Claims Present Challenge Of Actually Limiting Use

FDA Anti-Infective Drugs Advisory Committee cites need to prevent widespread prescribing but acknowledges poor antibiotic stewardship by the medical community; legislation could give FDA additional tools to regulate use and post-marketing surveillance.

Biomedical Reform Legislation Draft Could Be Released By January

At the final roundtable for the 21st Century Cures initiative in Washington, Chairman Upton promises swift action, and urges stakeholders to submit their ideas “as soon as possible.”

To Revolutionize Antibiotic Pipeline Start With Rapid Diagnostics

Point-of-care diagnostics can make antibiotic development faster, easier and cheaper, but creating them will be a bumpy ride, according to a recent discussion among government and industry officials.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel